Strategic funding AMILI recently secured Series A funding and has ongoing investor partnerships, signaling strong growth potential and interest from investors, which can be leveraged to approach collaborators and enterprise buyers in health systems seeking innovative gut microbiome solutions.

Clinical integration As the leading precision gut microbiome company in Asia with services from testing to interventions and a gut microbiome bank, AMILI can be positioned as a partner for hospitals, clinics, and insurers seeking to offer microbiome-based diagnostics, therapies, and restoration programs.

Expansion footprint With a focus on Southeast Asia and Greater Asia, AMILI’s expansion trajectory presents cross-border sales opportunities for multinational healthcare providers, academic partners, and government healthcare programs interested in scalable gut health initiatives.

Data and partnerships AMILI operates the world’s largest multi-ethnic Asian gut microbiome database and maintains active research collaborations, presenting a compelling case for enterprise deals around data access, co-development projects, and functional foods partnerships.

Clinical services breadth Offering a full spectrum from precision tests to probiotics, metabolic programs, and Microbiome Restoration Therapy, AMILI can upsell to clinics and wellness platforms seeking end-to-end gut health solutions and recurring revenue models.